Cell-type-specific delivery of therapeutics requires selectivity to prevent delivery to off-target cells. However, developing methods that provide the desired selectivity remains challenging. Toxins such as anthrax, botulinum and diphtheria toxin have been explored as delivery systems due to their ability to undergo endocytosis through interactions with cells via the toxin receptor-binding domain and subsequent endosomal escape, but they have issues with immunogenicity, limited target scope or their two-component nature. Roh et al. have now developed a modular delivery platform that addresses some of these limitations and is based on inactivated botulinum neurotoxin (BoNT).

治疗剂的细胞类型特异性递送需要选择性以防止递送至脱靶细胞。然而，开发提供所需选择性的方法仍然具有挑战性。炭疽、肉毒杆菌和白喉毒素等毒素已被探索作为递送系统，因为它们能够通过毒素受体结合域与细胞相互作用并随后发生内体逃逸，从而进行内吞作用，但它们存在免疫原性、靶标范围有限或它们的问题二元性质。罗等人。现在已经开发出一种模块化的交付平台，可以解决其中的一些限制，并且基于灭活的肉毒杆菌神经毒素 (BoNT)。